



Subject: Alternating Electrical Field Therapy*

Effective Date: September 29, 2015

Department(s): Utilization Management

Policy: Alternating electrical field therapy, also known as tumor treating field therapy (TTFields), is reimbursable under Plans administered by QualCare, Inc.

Objective: To assure proper and consistent reimbursement.

Procedure: Requests for alternating electric field therapy delivered by battery or power supply operated device (Optune™) - **HCPCS codes E0766, A4555**- will be approved when all of the following criteria in either section A or B below are met:

A.

1. A diagnosis of malignant neoplasm of the brain(**ICD-10 191.0-191.5**) specified as **glioblastoma multiforme(GBM)** on pathology review.
2. Standard brain radiation therapy with concurrent temozolomide chemotherapy has been completed.
3. The member has a documented performance status of ≥ 60 on the Karnofsky Performance Status

Scale(KPS) or 0 to 2 on the eastern Cooperative Oncology Group (ECOG) performance scale.

4. TTField therapy will be concurrent with temozolomide chemotherapy.

OR

B.

1. A diagnosis of malignant neoplasm of the brain(**ICD-10 191.0-191.5**) specified as **glioblastoma multiforme(GBM)** on pathology review with recurrence after receiving chemotherapy.
2. TTField therapy is being used as monotherapy.

Note: 2018 NCCN Guidelines® specify that TTField therapy is only an option for individuals whose tumor is in a supratentorial location (as specified by the ICD-10 code range above).

Authorization parameters: when the above criteria are met approval can be given for six months.

References

National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Central nervous system cancers.v.1.2018, accessed at NCCN.org

Stupp R, Taillibert S, Kanner A, Read W, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318(23):2306-2316(Dec)

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Central nervous system cancers.v.1.2016, accessed at NCCN.org

Stupp R, Taillibert S, Kanner AA, Kesari S, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015;314(23):2535-43(Dec)

Batchelor T. Initial postoperative therapy for glioblastoma and anaplastic astrocytoma. UpToDate, version 39.0, updated August 26 , 2016.accessed at UpToDate.com

National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Central nervous system cancers.v.1.2015, accessed at NCCN.org

Batchelor T, Shih HA, Carter BS. Management of high-grade recurrent gliomas. UpToDate, version 30.0 accessed at UpToDate.com

Wong T, Lok E, Swanson KD. An evidence-based review of alternating electric fields therapy for malignant gliomas. CurrTreat Options in Oncol. 2015;(16(40

Mrugala MM, Engelhard HH, Dinh Tran D, et al. Clinical practice experience with NovoTTF-100A™ System for glioblastoma: the patient registry dataset (PRiDe). Semin Oncol. 2014 Sep 11. pii: S0093-7754

Kirkpatrick JP,Sampson JH. Recurrent Malignant Gliomas. Semin Radiat Oncol. 2014;24(4):289-298(Oct)

Pless M, Droege C, von Moos R, et al. A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. 2013; 81(3):445-450.

De Bonis, P, Doglietto, F, Anile, C, Pompucci, A, Mangiola, A. Electric fields for the treatmentof glioblastoma. Expert review of neurotherapeutics. 2012 Oct;12(10):1181-4

Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012; 48(14):2192-2202.

Kirson ED, Dbaly V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 2007; 104(24):10152-10157.

Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004; 64(9):3288-3295.

Drafted By/Date: M.McNeil, MD 09/10/15
Approved By/Date: QM Committee 9/29/15
Revised By/Date: M. McNeil, MD 09/22/16
Approved By/Date: QM Committee 10/25/16
Reviewed w/o Revision By/Date: M McNeil, MD 05/18/18
Approved By/Date: QM Committee 06/19/18

*Consistent with Summary Plan Description (SPD). If there is discordance with the SPD, provisions of the SPD take precedence.